Long-term Safety of NIAGEN® Supplementation at High Doses Shows Potential for Improvement in Liver Health


Aarhus University Hospital and the University of Copenhagen (both from Denmark) “suggest further studies on NIAGEN should focus on therapeutic potential for liver health.”  Publicly traded ChromaDex Corp, the commercial sponsor, considers itself “an integrated, science-based nutraceutical company devoted to improving the way people age.” Their NIAGEN product is “a novel form of vitamin B3.”  The study was published in the American Journal of Clinical Nutrition.

Study lead included:

Jonas T. Treebak, MS, PhD


Niels Jessen, MD, PhD


TrialSite News looked into ChromaDex Corp. Based in Irvine, they are a small company with approximately 71 employees. For 2017 revenues are reported at $21.5 million; loss at -$11.3 million. 38.16% of stock held by insiders.  The largest institutional holders include Champion River Ventures and Pioneer Steep Holdings LTD. Stock price currently at $4.51 per share; 52 week high/low $2.86/$7.24. See their latest SEC 10K filing: https://www.sec.gov/Archives/edgar/data/1386570/000165495418002621/cdxc10k_dec302017.htm

View article here